Saturday, 26 November 2011

Osteo Bi-Flex Double Strength


Generic Name: chondroitin and glucosamine (kon DROI tin and gloo KOE sa meen)

Brand Names: Cosamin DS, Osteo Bi-Flex, Osteo Bi-Flex Double Strength, Osteo Bi-Flex Triple Strength, Pryflex, Relamine, Schiff Move Free, Schiff Move Free Caplets


What is Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?

Chondroitin is a naturally occurring substance formed of sugar chains. Chondroitin is believed to help the body maintain fluid and flexibility in the joints.


Glucosamine is sugar protein that is believed to help develop and renew cartilage (the hard connective tissue mainly located on bones near joints in the body), and keep it lubricated for better joint movement and flexibility.


The combination of chondroitin and glucosamine is widely used to aid in maintaining healthy joints. It is also used as a nutritional supplement in people with osteoarthritis or other inflammatory joint disorders.


Not all uses for chondroitin and glucosamine have been approved by the FDA. Chondroitin and glucosamine should not be substituted for medications prescribed for you by your doctor.

Chondroitin and glucosamine is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Chondroitin and glucosamine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?


Not all uses for chondroitin and glucosamine have been approved by the FDA. Chondroitin and glucosamine should not be substituted for medications prescribed for you by your doctor.

Chondroitin and glucosamine is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.


Before using chondroitin and glucosamine, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use chondroitin and glucosamine if you have diabetes, a bleeding or blood clotting disorder such as hemophilia, if you have allergies to certain drugs, if you are overweight, or if you are on a low-salt diet.


Use chondroitin and glucosamine as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.


Do not take chondroitin and glucosamine without the advice of a healthcare provider if you are using insulin, or a blood thinner such as warfarin (Coumadin). Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin and glucosamine. Chitosan can make it harder for your body to absorb chondroitin.

What should I tell my healthcare provider before taking Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?


Before using chondroitin and glucosamine, talk to your doctor, pharmacist, herbalist, or other healthcare provider. You may not be able to use chondroitin and glucosamine if you have:



  • diabetes;




  • a bleeding or blood clotting disorder such as hemophilia;




  • if you have allergies to certain drugs;




  • if you are overweight; or




  • if you are on a low-salt diet.




Chondroitin and glucosamine may or may not be harmful to an unborn baby. Do not use this product without talking to a healthcare provider if you are pregnant or plan to become pregnant during treatment. It is not known whether chondroitin and glucosamine can pass into breast milk or if it could harm a nursing baby. Ask your healthcare provider before using chondroitin and glucosamine if you are breast-feeding a baby.

How should I take Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?


When considering the use of herbal supplements, seek the advice of your doctor. You may also consider consulting a practitioner who is trained in the use of herbal/health supplements.


If you choose to take chondroitin and glucosamine, use it as directed on the package or as directed by your doctor, pharmacist, or other healthcare provider. Do not use more of chondroitin and glucosamine than is recommended on the label.


Chondroitin and glucosamine is usually taken 1 or 2 times per day. You may need to take the medication 3 times per day for the first couple of months of treatment. Follow your doctor's instructions.


Glucosamine may increase the glucose (sugar) levels in your blood. If you have diabetes, you may need to check your blood sugar more often while taking this medication. You may also need to adjust your insulin dosage. Do not change your dose or medication schedule without advice from your doctor.


Chondroitin and glucosamine may be only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.


Store this medication at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?


Avoid taking chitosan (usually marketed as a weight-loss product) while you are taking chondroitin and glucosamine. Chitosan can make it harder for your body to absorb chondroitin.

Osteo Bi-Flex Double Strength (chondroitin and glucosamine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:



  • mild nausea, upset stomach;




  • heartburn; or




  • diarrhea.



This is not a complete list of side effects and others may occur. Tell your doctor, pharmacist, herbalist, or other healthcare provider about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Osteo Bi-Flex Double Strength (chondroitin and glucosamine)?


Do not take chondroitin and glucosamine without the advice of a healthcare provider if you are using any of the following medications:

  • insulin; or




  • a blood thinner such as warfarin (Coumadin).



This list is not complete and other drugs may interact with chondroitin and glucosamine. Tell your healthcare provider about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Osteo Bi-Flex Double Strength resources


  • Osteo Bi-Flex Double Strength Use in Pregnancy & Breastfeeding
  • Osteo Bi-Flex Double Strength Drug Interactions
  • 0 Reviews for Osteo Bi-Flex Double Strength - Add your own review/rating


  • Osteo Bi-Flex Triple Strength caplets

  • Relamine MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Osteo Bi-Flex Double Strength with other medications


  • Dietary Supplementation
  • Osteoarthritis


Where can I get more information?


  • Consult with a licensed healthcare professional before using any herbal/health supplement. Whether you are treated by a medical doctor or a practitioner trained in the use of natural medicines/supplements, make sure all your healthcare providers know about all of your medical conditions and treatments.


Pantoprazol gamma




Pantoprazol gamma may be available in the countries listed below.


Ingredient matches for Pantoprazol gamma



Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol gamma in the following countries:


  • Germany

International Drug Name Search

Tuesday, 22 November 2011

ChiRhoStim


ChiRhoStim is a brand name of secretin, approved by the FDA in the following formulation(s):


CHIRHOSTIM (secretin synthetic human - for solution; intravenous)



  • Manufacturer: CHIRHOCLIN

    Approval date: April 9, 2004

    Strength(s): 16MCG/VIAL [RLD]


  • Manufacturer: CHIRHOCLIN

    Approval date: June 21, 2007

    Strength(s): 40MCG/VIAL

Has a generic version of ChiRhoStim been approved?


No. There is currently no therapeutically equivalent version of ChiRhoStim available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ChiRhoStim. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with ChiRhoStim.

See also...

    Pacific Buspirone




    Pacific Buspirone may be available in the countries listed below.


    Ingredient matches for Pacific Buspirone



    Buspirone

    Buspirone hydrochloride (a derivative of Buspirone) is reported as an ingredient of Pacific Buspirone in the following countries:


    • New Zealand

    International Drug Name Search

    Wednesday, 16 November 2011

    Durol




    Durol may be available in the countries listed below.


    Ingredient matches for Durol



    Carvedilol

    Carvedilol is reported as an ingredient of Durol in the following countries:


    • Bangladesh

    International Drug Name Search

    Saturday, 12 November 2011

    Viveo




    Viveo may be available in the countries listed below.


    Ingredient matches for Viveo



    Tolperisone

    Tolperisone hydrochloride (a derivative of Tolperisone) is reported as an ingredient of Viveo in the following countries:


    • Germany

    International Drug Name Search

    Thursday, 10 November 2011

    Supreme




    Supreme may be available in the countries listed below.


    Ingredient matches for Supreme



    Sulfamethoxazole

    Sulfamethoxazole is reported as an ingredient of Supreme in the following countries:


    • Peru

    Trimethoprim

    Trimethoprim is reported as an ingredient of Supreme in the following countries:


    • Peru

    International Drug Name Search

    Tuesday, 8 November 2011

    Toltem




    Toltem may be available in the countries listed below.


    Ingredient matches for Toltem



    Tolterodine

    Tolterodine tartrate (a derivative of Tolterodine) is reported as an ingredient of Toltem in the following countries:


    • Argentina

    International Drug Name Search

    Sunday, 6 November 2011

    Boniva


    Boniva is a brand name of ibandronate, approved by the FDA in the following formulation(s):


    BONIVA (ibandronate sodium - injectable; intravenous)



    • Manufacturer: ROCHE

      Approval date: January 6, 2006

      Strength(s): EQ 3MG BASE/3ML [RLD]

    BONIVA (ibandronate sodium - tablet; oral)



    • Manufacturer: ROCHE

      Approval date: March 24, 2005

      Strength(s): EQ 150MG BASE [RLD]

    Has a generic version of Boniva been approved?


    No. There is currently no therapeutically equivalent version of Boniva available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Boniva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Diphosphonate derivatives, pharmaceutical compositions and methods of use
      Patent 4,927,814
      Issued: May 22, 1990
      Inventor(s): Gall; Rudi & Bosies; Elmar
      Assignee(s): Boehringer Mannheim GmbH
      The present invention provides disphosphonates of the general formula: ##STR1## wherein R.sub.1 is a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical of 1-9 carbon atoms which is optionally substituted by phenyl or cyclohexyl, R.sub.2 is cyclohexyl or cyclohexylmethyl, benzyl or a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon of 4 to 18 carbon atoms which is optionally substituted by phenyl or oxygen wherein the oxygen can be esterified or etherified, R.sub.3 is hydrogen or a straight-chain or branched alkyl of 1-4 carbon atoms, X is a straight-chain or branched alkylene chain of 1-6 carbon atoms and Y is hydrogen, hydroxyl or an amino group optionally substituted by alkyl radicals of 1-6 carbon atoms; as well as the pharmacologically acceptable salts thereof. The present invention also provides processes for the preparation of these diphosphonic acid derivatives and pharmaceutical compositions containing them for the prophyllaxis treatment of diseases or disturbances of calcium metabolism such as osteoporsis, Pagets disease, Bechterew's disease, bone metastases, urolithiasis, heterotropic ossifications, rheumatoid arthritis, osteoarthritis and degenerative arthrosis.
      Patent expiration dates:

      • March 17, 2012
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
        ✓ 
        Drug substance
        ✓ 
        Drug product


      • March 17, 2012
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS
        ✓ 
        Drug substance
        ✓ 
        Drug product




    • Pharmaceutical agents containing diphosphonic acids and salts thereof
      Patent 5,662,918
      Issued: September 2, 1997
      Inventor(s): Winter; Gerhard & Pichler; Bernhard & Woog; Heinrich & Heller; Werner
      Assignee(s): Boehringer Mannheim GmbH
      The invention concerns pharmaceutical preparations that are stable on storage, which contain at least one diphosphonic acid and/or at least one physiologically acceptable salt of such an acid as the active substance.
      Patent expiration dates:

      • September 2, 2014
        ✓ 
        Drug product




    • Oral pharmaceutical preparation containing ibandronat
      Patent 6,143,326
      Issued: November 7, 2000
      Inventor(s): Mockel; Jorn & Gabel; Rolf-Dieter & Woog; Heinrich
      Assignee(s): Roche Diagnostics GmbH
      The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.
      Patent expiration dates:

      • April 21, 2017
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS




    • Pharmaceutical composition containing diphosphonic acid or salt thereof
      Patent 6,294,196
      Issued: September 25, 2001
      Inventor(s): Gabel; Rolf-Dieter & Preis; Walter & Woog; Heinrich
      Assignee(s): Hoffmann-La Roche Inc.
      The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.
      Patent expiration dates:

      • October 7, 2019
        ✓ 
        Drug product




    • Method of treatment using bisphosphonic acid
      Patent 7,192,938
      Issued: March 20, 2007
      Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
      Assignee(s): Hoffmann-La Roche Inc.
      The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
      Patent expiration dates:

      • May 6, 2023
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID




    • Method of treatment using bisphosphonic acid
      Patent 7,410,957
      Issued: August 12, 2008
      Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
      Assignee(s): Hoffmann-La Roche Inc.
      The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
      Patent expiration dates:

      • May 6, 2023
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS




    • Method of treatment using bisphosphonic acid
      Patent 7,718,634
      Issued: May 18, 2010
      Inventor(s): Bauss; Frieder & Pichler; Bernhard & Turley; Stephen
      Assignee(s): Hoffman-La Roche Inc.
      The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
      Patent expiration dates:

      • May 6, 2023
        ✓ 
        Patent use: TREATMENT AND PREVENTION OF OSTEOPOROSIS



    See also...

    • Boniva Consumer Information (Drugs.com)
    • Boniva Consumer Information (Drugs.com)
    • Boniva Consumer Information (Wolters Kluwer)
    • Boniva Consumer Information (Cerner Multum)
    • Boniva Advanced Consumer Information (Micromedex)
    • Boniva Intravenous Advanced Consumer Information (Micromedex)
    • Boniva AHFS DI Monographs (ASHP)
    • Boniva IV Injection Consumer Information (Drugs.com)
    • Ibandronate Consumer Information (Wolters Kluwer)
    • Ibandronate Consumer Information (Cerner Multum)
    • Bondronat Advanced Consumer Information (Micromedex)
    • Ibandronate Intravenous Advanced Consumer Information (Micromedex)
    • Ibandronate Oral, Injection Advanced Consumer Information (Micromedex)
    • Ibandronate Sodium AHFS DI Monographs (ASHP)

    Macrosan




    Macrosan may be available in the countries listed below.


    Ingredient matches for Macrosan



    Nitrofurantoin

    Nitrofurantoin is reported as an ingredient of Macrosan in the following countries:


    • Chile

    International Drug Name Search

    Saturday, 5 November 2011

    CO Etidronate




    CO Etidronate may be available in the countries listed below.


    Ingredient matches for CO Etidronate



    Etidronic Acid

    Etidronic Acid is reported as an ingredient of CO Etidronate in the following countries:


    • Canada

    International Drug Name Search

    Friday, 4 November 2011

    Orciprenaline Sulphate




    Orciprenaline Sulphate may be available in the countries listed below.


    Ingredient matches for Orciprenaline Sulphate



    Orciprenaline

    Orciprenaline Sulphate (BANM) is also known as Orciprenaline (Rec.INN)

    International Drug Name Search

    Glossary

    BANMBritish Approved Name (Modified)
    Rec.INNRecommended International Nonproprietary Name (World Health Organization)

    Click for further information on drug naming conventions and International Nonproprietary Names.

    Tuesday, 1 November 2011

    Pyridinol Carbamate




    Pyridinol Carbamate may be available in the countries listed below.


    Ingredient matches for Pyridinol Carbamate



    Pyricarbate

    Pyridinol Carbamate (JAN) is also known as Pyricarbate (Rec.INN)

    International Drug Name Search

    Glossary

    JANJapanese Accepted Name
    Rec.INNRecommended International Nonproprietary Name (World Health Organization)

    Click for further information on drug naming conventions and International Nonproprietary Names.